SapVax is advancing discoveries made by researchers from the University of Auckland in New Zealand. Their academic founders have developed a novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines. The Sapvax team is developing a pipeline of products for thetreatment of different cancers, with an initial focus on tumors expressing NY-ESO-1.

Biotechnology

Health Care

SapVax, LLC

SapVax, LLC's headquarters in Cleveland, OH, United States

Description

People

Jobs